Zenotech Laboratories Ltd

Zenotech Lab. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Zenotech Laboratories Ltd

₹ 44.3 -2.44%
24 Jul - close price
zenotechlab.com BSE: 532039
About

Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]

Key Points

Business Overview:[1]
ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty
generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products

Website BSE
  • Market Cap ₹ 270 Cr.
  • Current Price ₹ 44.3
  • High / Low ₹ 62.0 / 33.6
  • Stock P/E
  • Book Value ₹ 15.8
  • Dividend Yield 0.00 %
  • ROCE -9.08 %
  • ROE -12.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 2.80 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -14.8% over last 3 years.
  • Debtor days have increased from 72.3 to 96.1 days.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2006 Sep 2006
2.83 5.27
4.30 3.98
Operating Profit -1.47 1.29
OPM % -51.94% 24.48%
0.10 0.23
Interest 0.30 0.45
Depreciation 0.12 0.34
Profit before tax -1.79 0.73
Tax % 0.00% 0.00%
-1.79 0.73
EPS in Rs 0.14
Raw PDF
Upcoming result date: 28 July 2026

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
12 13 8 6 7
15 19 18 24 16
Operating Profit -3 -6 -10 -18 -9
OPM % -20% -49% -121% -292% -143%
0 9 2 5 2
Interest 1 2 3 1 2
Depreciation 0 2 3 3 3
Profit before tax -3 -1 -14 -18 -13
Tax % 6% -250% 17% 0% -0%
-4 2 -16 -18 -13
EPS in Rs 0.32 -2.64 -2.88 -2.05
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -20%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 29%
Stock Price CAGR
10 Years: 1%
5 Years: -5%
3 Years: -10%
1 Year: -28%
Return on Equity
10 Years: %
5 Years: -13%
3 Years: -15%
Last Year: -12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
Equity Capital 16 29 34 34 34
Reserves 6 25 92 74 62
31 36 19 17 10
21 10 8 5 4
Total Liabilities 74 100 153 131 111
16 60 61 62 71
CWIP 40 9 15 24 13
Investments 0 0 0 0 0
19 30 77 45 27
Total Assets 74 100 153 131 111

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
-16 -7 -3 -16 -10
-56 -15 -67 20 29
74 22 70 -4 -8
Net Cash Flow 2 -0 -0 1 11
Free Cash Flow -70 -22 -13 -28 -11
CFO/OP 619% 109% 23% 82% 102%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
Debtor Days 145 273 85 36 96
Inventory Days 139 331 575 172 279
Days Payable 451 455 421 226 253
Cash Conversion Cycle -167 149 240 -18 123
Working Capital Days 55 279 196 250 286
ROCE % 2% -9% -12% -9%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Permanent Employees
count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Sale of Own Products (Oncology) Revenue
INR thousands ・Standalone data
Sale of Services - Contract Manufacturing (Conversion Charges) Revenue
INR thousands ・Standalone data
Lease Rental Income (Biotech facility & equipment lease to Sun Pharma)
INR thousands ・Standalone data
Total HR Strength (engaged workforce)
count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84% 68.84%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
0.98% 0.98% 0.98% 0.98% 0.98% 0.98% 0.98% 0.98% 0.98% 0.98% 0.98% 0.98%
30.17% 30.17% 30.17% 30.16% 30.18% 30.18% 30.18% 30.17% 30.18% 30.18% 30.17% 30.17%
No. of Shareholders 9,5899,7629,8199,75010,64110,66710,69010,66110,67010,46410,30110,161

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue